Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Summary

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.

Timeline

Start

2023-12-12

Primary completion

2026-09

Completion

2026-12

Drugs

Indications